<DOC>
	<DOCNO>NCT00560495</DOCNO>
	<brief_summary>RATIONALE : Ammonium tetrathiomolybdate may stop growth non-small cell lung cancer block blood flow tumor . Radiation therapy use high-energy x-ray kill tumor cell . Giving ammonium tetrathiomolybdate together radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect give radiation therapy together ammonium tetrathiomolybdate treating patient stage I , stage II , stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Radiation Therapy Ammonium Tetrathiomolybdate Treating Patients With Stage I , Stage II , Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess acute toxicity combine antiangiogenic copper reduction ammonium tetrathiomolybdate ( TM ) standard external-beam radiotherapy patient stage I-IIIB non-small cell lung cancer . Secondary - To measure change biological marker angiogenesis ( i.e. , ELISA analysis serum bFGF , VEGF , TGF-beta , IL-6 , IL-8 ) affect TM radiotherapy imaging technique ( technetium 99m sestamibi ) know correlate intratumoral angiogenesis . - To follow late toxicity exist angiogenic inhibition copper reduction agent TM combine standard external-beam radiotherapy patient . - To collect tumor response , recurrence rate , survival data patient . OUTLINE : - Induction phase : Patients receive oral ammonium tetrathiomolybdate ( TM ) 4 time daily 3 week . - Radiotherapy : Patients undergo radiotherapy daily , 5 day week , 6-7 week along concurrent TM . - Maintenance phase : Patients continue receive TM total 1 year . Blood collect periodically analysis laboratory outcome ELISA technetium 99m sestamibi scan . Biomarkers may include VEGF , bFGF , TGF-beta , interleukin ( IL ) -6 , IL-8 . After completion study therapy , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Tetrathiomolybdate</mesh_term>
	<mesh_term>Molybdenum</mesh_term>
	<mesh_term>Technetium Tc 99m Sestamibi</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) meeting follow criterion : Squamous , large cell undifferentiated , adenocarcinoma Sputum cytology acceptable evidence cell type Cytologic specimen obtain brushing , wash , needle aspiration define lesion allow Stage IIIIB disease No evidence distant metastasis Planning receive definitive radiotherapy alone postoperative radiotherapy ( gross residual disease positive margin ) Medically inoperable disease chemotherapy surgery refuse Mediastinal lymph node must evaluate either mediastinoscopy PET scan , unless definitive CTpositive mediastinal disease note If patient tolerate mediastinoscopy PET available , technetium 99m sestamibi scan allow assessment mediastinum No stage IIIB disease pleural effusion stage IV disease No small cell lung cancer mix small cell/nonsmall cell histology PATIENT CHARACTERISTICS : SWOG performance status 02 Hemoglobin ≥ 9.0 g/dL WBC ≥ 3,000/mm³ ANC ≥ 1,200/mm³ Platelet count ≥ 80,000/mm³ Creatinine &lt; 1.8 mg/dL Prior malignancy allow disease free ≥ 5 year Nonmelanoma skin cancer allow within 5 year Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No grade 3 hemoptysis ( hemoptysis require transfusion , radiation oncologist concern 3week delay treatment ) No pneumonia due bronchial obstruction ( highgrade bronchial obstruction radiation oncologist concern 3week delay treatment ) No transfusion dependence require &gt; 2 unit pack RBCs every 2 week 28 day No medically serious acute chronic medical condition unstable and/or require intensive management PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior thoracic radiation allow new lesion treat absolutely overlap previous treatment field At least 3 week since prior surgery No concurrent chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
</DOC>